Mode
Text Size
Log in / Sign up

Preoperative inflammatory markers linked to survival in resectable NSCLCSimple Blood Work Could Predict Lung Cancer Surgery Outcomes

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider preoperative inflammatory markers as prognostic tools for risk stratification in resectable NSCLC.

This was a multi-center retrospective cohort study of 460 patients undergoing primary resection for resectable non-small cell lung cancer (NSCLC), with an external validation cohort of 50 patients. The study measured preoperative inflammatory markers (NLR, PLR, SII, SIRI) 15 days prior to surgery.

Elevated levels of NLR, PLR, SII, and SIRI were significantly associated with poorer overall survival (OS). The 3-year OS rate was 83.6% and the 5-year OS rate was 72.6%. Elevated markers were also significantly associated with poorer progression-free survival (PFS), with a 3-year PFS rate of 82.4% and a 5-year PFS rate of 75.0%.

Lymphatic metastasis, antibacterial use, NLR, and SIRI were independent predictors of OS. Lymphatic metastasis, radiotherapy, antibacterial use, NLR, and SIRI were independently associated with PFS. External validation showed SIRI had good discrimination with a concordance index of 0.803 (95% CI: 0.644–0.962).

Safety and tolerability were not reported. Key limitations include the retrospective design, restriction to resectable NSCLC patients, and a small external validation cohort (n=50). The study suggests preoperative inflammatory markers, particularly SIRI, may aid in risk stratification for individualized treatment strategies, but results are associative and not causal.

Why Inflammation Levels Matter Now

Patients want to know their odds. They want to plan their lives. Uncertainty creates fear for everyone involved.

Doctors usually look at the tumor size. They check how far it has spread. But the body tells a different story.

The body reacts to cancer like a fire. It sends immune cells to fight the threat. Sometimes, this reaction is too strong.

The Surprising Shift in Care

This study looked at blood markers instead. They measured how the body was reacting before the cut. This happens weeks before the operation.

Think of inflammation like a traffic jam. Too many cars cause a backup. Too much inflammation causes problems.

Researchers reviewed records from 460 patients. They checked blood tests taken 15 days prior. They also tested these results on another group.

High inflammation levels linked to poorer survival. Patients with lower levels did much better. The risk was clear in the data.

What the Numbers Mean for You

One specific score worked better than others. It combined different blood cell counts. This score helped predict who might get sick again.

This doesn’t mean this treatment is available yet.

The study used advanced computer tools. These tools found patterns humans might miss. They confirmed the blood test was reliable.

Experts say this fits into bigger goals. Doctors want to personalize care for each person. This tool helps them make smarter choices.

A New Tool for Doctors

It does not replace standard tests. It adds important information to the mix. It helps weigh the risks carefully.

You should not panic about your blood work. These tests are not new. But they are being used differently now.

This study looked at past records only. It did not test a new drug. More research is needed to confirm these results.

What Happens Next in Research

Doctors need to prove this works everywhere. They must test it on larger groups. Approval takes time and careful review.

Future trials will check if this helps patients live longer. It might change how surgery is planned. But for now, it remains a research finding.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
PurposeThis study aimed to assess the prognostic significance of the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), and systemic inflammation response index (SIRI), measured 15 days prior to surgery, in patients undergoing primary resection for NSCLC.MethodsWe retrospectively analyzed data from 460 NSCLC patients treated at two comprehensive hospitals, along with another 50 patients for external validation. Optimal cut-off values for NLR, PLR, SII, and SIRI were determined. Kaplan–Meier analysis was performed to estimate overall survival (OS) and progression-free survival (PFS). Univariate and multivariate Cox regression analyses were conducted to identify independent prognostic factors. To evaluate and validate the reliability of prognostic factor selection, three commonly used machine learning methods—LASSO, Random Forest, and Support Vector Machine (SVM)—were applied. The systemic inflammatory markers were subjected to external validation in an independent cohort, encompassing discriminative analysis, calibration analysis, and clinical decision curve analysis (DCA), with a final evaluation of the SIRI’s underlying rationale.ResultsThe optimal cut-off values for NLR, PLR, SII, and SIRI were 3.470, 186, 853.71, and 1.66, respectively. Kaplan–Meier curves demonstrated that elevated levels of all four markers were significantly associated with poorer OS and PFS. The 3- and 5-year OS rates were 83.6 and 72.6%, while the 3- and 5-year PFS rates were 82.4 and 75.0%, respectively. Univariate analysis identified several factors significantly associated with survival, including inflammatory markers, smoking, antibacterial use, lymphatic metastasis, radiotherapy, intraoperative blood loss, and preoperative albumin levels. Multivariate analysis further revealed that lymphatic metastasis, antibacterial use, NLR, and SIRI were independent predictors of OS, whereas lymphatic metastasis, radiotherapy, antibacterial use, NLR, and SIRI were independently associated with PFS. Consistently, machine learning methods also highlighted NLR and SIRI as reliable independent prognostic indicators in patients with resectable NSCLC. SIRI showed good discrimination with a concordance index of 0.803 (95% CI: 0.644–0.962) for external validation.ConclusionPreoperative systemic inflammatory markers, particularly SIRI, are strong and independent prognostic indicators of PFS in patients with resectable NSCLC. Among these, a low SIRI may provide superior risk stratification for identifying high-risk patients and informing individualized treatment strategies.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.